The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.
 
Xiaojian Qin
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Weiqing Han
Research Funding - Jiangsu Hengrui Medicine
 
Hong Luo
Research Funding - Jiangsu Hengrui Medicine
 
Chuanjun Du
Research Funding - Jiangsu Hengrui Medicine
 
Qing Zou
Research Funding - Jiangsu Hengrui Medicine
 
Zhongquan Sun
Research Funding - Jiangsu Hengrui Medicine
 
Chaohong He
Research Funding - Jiangsu Hengrui Medicine
 
Shaoxing Zhu
Research Funding - Jiangsu Hengrui Medicine
 
Tie Chong
Research Funding - Jiangsu Hengrui Medicine
 
Xin Yao
Research Funding - Jiangsu Hengrui Medicine
 
Ben Wan
Research Funding - Jiangsu Hengrui Medicine
 
Weijie Gu
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Dingwei Ye
Research Funding - Jiangsu Hengrui Medicine